Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer

Derek Raghavan, Earle Burgess, Kris E. Gaston, Michael R. Haake, Steven B. Riggs

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Deeply invasive bladder cancer, representing approximately 20% of incident cases, is cured by radical cystectomy or radiotherapy in less than 50% of cases. In an effort to improve cure rates, based on objective response rates in metastatic disease of 40%-70% from combination chemotherapy regimens, systemic chemotherapy has been incorporated into programs of definitive treatment for this disease. Several randomized trials and a meta-analysis have confirmed a survival benefit from neoadjuvant chemotherapy followed by definitive local treatment, reflecting both median survival figures and cure rates. Despite several promising phase II trials, no randomized trial of classical adjuvant chemotherapy for bladder cancer has demonstrated an overall survival benefit, despite increments in disease-free survival. Molecular prognostication has been studied in an effort to improve the utility of systemic therapy for invasive non-metastatic bladder cancer, but randomized trials have not shown associated survival benefit. Despite level 1 evidence of a survival benefit from neoadjuvant MVAC (methotrexate, vinblastine, doxorubicin [Adriamycin], cisplatin) or cisplatin, methotrexate, and vinblastine (CMV) chemotherapy, more than 50% of incident cases do not receive such treatment.

Original languageEnglish (US)
Pages (from-to)588-597
Number of pages10
JournalSeminars in oncology
Issue number5
StatePublished - Oct 2012
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer'. Together they form a unique fingerprint.

Cite this